TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9388086

Group type: EXPERIMENTAL
Intervention: Accelerated Diagnostic Protocol (ADP)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control (Inpatient treatment)
Number of subjects: 165
Study: 7999471

Group type: EXPERIMENTAL
Intervention: Synthetic retinoid (4-hydroxyphenylretinamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic mastectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pseudopregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ideal combination oral contraceptive
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LHRH agonist oophorectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modification of estrogen metabolism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suppression of ornithine decarboxylase induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of growth factors
Number of subjects: 0
Study: 3297938

Group type: EXPERIMENTAL
Intervention: 100 mg pirenzepine tablets
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30088009

Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control intervention (home safety)
Number of subjects: 279
Study: 27881559

Group type: EXPERIMENTAL
Intervention: CSL112 (2 g apoA‐I per dose)
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: High-dose CSL112 (6 g apoA‐I per dose)
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: CSL112 (2 g apoA‐I per dose) and High-dose CSL112 (6 g apoA‐I per dose)
Number of subjects: 1258
Study: 23445124

Group type: EXPERIMENTAL
Intervention: 4 years of early intervention (EI) service
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 2 years of early intervention (EI) service
Number of subjects: 360

Group type: COMPARATOR
Intervention: 4 years of standard care
Number of subjects: 360
Study: 22554598

Group type: EXPERIMENTAL
Intervention: 10 mg prasugrel
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 30 mg prasugrel
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 60 mg prasugrel
Number of subjects: 64
Study: 20808309

Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 at doses of 160 or 320 IU m(‐2)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 with undetectable circulating arginine for >=4 weeks
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 with undetectable circulating arginine for <4 weeks
Number of subjects: 71
Study: 18296324

Group type: EXPERIMENTAL
Intervention: Calcium fortified milk (Ca milk)
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D fortified milk (CaD milk)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group (unsupplemented)
Number of subjects: 345
Study: 16049208

Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extracts (three preparations: supercritical carbon dioxide, 60% ethanol, 20% ethanol)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia extracts
Number of subjects: 399
Study: 12823436

Group type: EXPERIMENTAL
Intervention: 5% vitamin C cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excipient (control)
Number of subjects: 0
Study: 10383011

Group type: COMPARATOR
Intervention: Calcium acetate (CaAC)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Calcium ketoglutarate (CaKE)
Number of subjects: 28
Study: 8538344

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Number of subjects: 119

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography (ERC)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy with instrumental exploration
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Overall morbidity rate
Number of subjects: 119
Study: 1523350

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg pm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probucol 500 mg bi
Number of subjects: 0
Study: 6592034

Group type: EXPERIMENTAL
Intervention: Multiagent induction and single-agent maintenance chemotherapy with randomization to an immunotherapy arm.
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Elective surgical splenectomy performed for 42 patients at the completion of 3 months of induction therapy.
Number of subjects: 87
Study: 30279015

Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg twice daily
Number of subjects: 472

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 472
Study: 29546669

Group type: EXPERIMENTAL
Intervention: Transplantation of collagen/UC-MSCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transplantation of UC-MSCs
Number of subjects: 0
Study: 27397802

Group type: EXPERIMENTAL
Intervention: Rehabilitation through self‐management program (intervention group)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 141
Study: 24284444

Group type: EXPERIMENTAL
Intervention: 1.6 g · kg(‐1) · d(‐1) protein (2 × RDA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2.4 g · kg(‐1) · d(‐1) protein (3 × RDA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.8 g · kg(‐1) · d(‐1) protein (RDA)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Energy deficit (ED)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High-protein diets
Number of subjects: 39
Study: 21309652

Group type: EXPERIMENTAL
Intervention: Early hard palate repair (EarlyHPR) at 12 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Late hard palate unrepaired (LateHPU) at 36 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (matched for gender and age)
Number of subjects: 34
Study: 20456437

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 122

Group type: COMPARATOR
Intervention: Bimatoprost, Latanoprost, Travoprost
Number of subjects: 122
Study: 17389553

Group type: EXPERIMENTAL
Intervention: Arundic acid 2 mg/kg/h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arundic acid 4 mg/kg/h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arundic acid 6 mg/kg/h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arundic acid 8 mg/kg/h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arundic acid 10 mg/kg/h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arundic acid 12 mg/kg/h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arundic acid (all doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arundic acid (elderly patients)
Number of subjects: 48
Study: 16314642

Group type: EXPERIMENTAL
Intervention: Arm A: cyclophosphamide/doxorubicin and surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm B: carboplatin, etoposide, ifosfamide, and surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MYCN nonamplified, hyperdiploid tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MYCN nonamplified, diploid tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MYCN amplified, hyperdiploid tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MYCN amplified, diploid tumors
Number of subjects: 0
Study: 11923692

Group type: EXPERIMENTAL
Intervention: Rapa
Number of subjects: 2

Group type: COMPARATOR
Intervention: MMF
Number of subjects: 2
Study: 9449497

Group type: EXPERIMENTAL
Intervention: Bedding encasement with microfine fibers (Allerguard encasing)
Number of subjects: 57
Study: 7618964

Group type: EXPERIMENTAL
Intervention: Pouch and Roux‐en‐Y (PR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simple Roux‐en‐Y (RY)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pouch and interposition (PI)
Number of subjects: 30
Study: 2404087

Group type: EXPERIMENTAL
Intervention: IV oxacillin
Number of subjects: 92

Group type: COMPARATOR
Intervention: IV placebo using D5W
Number of subjects: 92

Group type: COMPARATOR
Intervention: Change of the catheter to a new site every 72 hours
Number of subjects: 92
Study: 326847

Group type: EXPERIMENTAL
Intervention: metaproterenol 0.5% nebulized in physiologic saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: isoproterenol 0.05% nebulized in physiologic saline
Number of subjects: 30
Study: 31630690

Group type: EXPERIMENTAL
Intervention: FiO2-C (in addition to routine manual control (RMC) of FiO2)
Number of subjects: 2340

Group type: COMPARATOR
Intervention: RMC only (control group)
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: FiO2-C (in addition to RMC)
Number of subjects: 2340
Study: 28539618

Group type: EXPERIMENTAL
Intervention: STII+ exenatide
Number of subjects: 129

Group type: COMPARATOR
Intervention: STII only
Number of subjects: 129
Study: 26222126

Group type: EXPERIMENTAL
Intervention: TAK-085 4 g/day
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: TAK-085 2 g/day
Number of subjects: 210

Group type: COMPARATOR
Intervention: EPA-E 1.8 g/day
Number of subjects: 210
Study: 23277248

Group type: EXPERIMENTAL
Intervention: Methylphenidate (30 mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 62
Study: 21502572

Group type: EXPERIMENTAL
Intervention: Revacept 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Revacept 20 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Revacept 40 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Revacept 80 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Revacept 160 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no Revacept)
Number of subjects: 30
Study: 19814947

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both (Olanzapine and Risperidone)
Number of subjects: 46
Study: 16332417

Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 20 microg ethinyl estradiol plus 0.15 mg desogestrel
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 0.100 mg levonorgestrel
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 0.75 mg of gestodene
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oligomenorrhoic untreated women
Number of subjects: 15
Study: 12908665

Group type: EXPERIMENTAL
Intervention: Second generation 'atypical' antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 0
Study: 11103221

Group type: EXPERIMENTAL
Intervention: 200 ml grape-skin extract in water (1 mg extract/ml) at each of three daily meals (31.3 mg total phenolics, including 9.0 mg catechin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Experimental diet without grape-skin extract
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Grape-skin extract intervention
Number of subjects: 15
Study: 9200766

Group type: EXPERIMENTAL
Intervention: Bayesian forecasting model for patients with cirrhosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bayesian forecasting model for patients without cirrhosis
Number of subjects: 0
Study: 8267433

Group type: EXPERIMENTAL
Intervention: PC-coated chest drainage tubes
Number of subjects: 102

Group type: COMPARATOR
Intervention: Noncoated chest drainage tubes
Number of subjects: 102
Study: 3535358

Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 31377190

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EG)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo-like stretching (PG)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Rest (RG)
Number of subjects: 151
Study: 30049591

Group type: EXPERIMENTAL
Intervention: Three phlebotomies (every 3 weeks) and lipid‐lowering dietary counseling
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lipid‐lowering dietary counseling
Number of subjects: 86
Study: 27188329

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) plus Methotrexate (MTX)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Traditional DMARD therapy
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: SAA levels
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Disease activity score of 28 joints (DAS28) using SAA levels
Number of subjects: 594
Study: 24769123

Group type: EXPERIMENTAL
Intervention: Interferential current stimulation (IFC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22252346

Group type: EXPERIMENTAL
Intervention: 60% feed restriction on d 4, 5, and 6 plus 1,500 mg/kg of quercetin (FR60Q)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60% feed restriction on d 4, 5, and 6 (FR60)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ad libitum feeding (control)
Number of subjects: 0
Study: 19836899

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (SD)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Partial Sleep Deprivation (4.5h of sleep)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Regular Sleep (7h of sleep)
Number of subjects: 7
Study: 18033957

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticlopidine 200 mg once daily
Number of subjects: 0
Study: 15675976

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 18
Study: 12105164

Group type: EXPERIMENTAL
Intervention: EP-guided therapy with ICD
Number of subjects: 0

Group type: COMPARATOR
Intervention: EP-guided therapy without ICD
Number of subjects: 0
Study: 10544403

Group type: EXPERIMENTAL
Intervention: Blue filters
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Optimal filters
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Placebo filters
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (no filters)
Number of subjects: 113
Study: 8786248

Group type: EXPERIMENTAL
Intervention: Endurance training (treadmill walking, stair climbing, or both, 3 times per week for 40 minutes at 70-85% of maximal heart rate reserve for 16 weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Endurance training and Non-exercising control
Number of subjects: 43
Study: 2184848

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG fermented yoghurt
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pasteurized regular yoghurt (placebo)
Number of subjects: 16
Study: 7407022

Group type: EXPERIMENTAL
Intervention: Aphasia type (4 levels)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Expectancy (4 levels)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lexico-syntactic abilities (2 levels)
Number of subjects: 50
Study: 31559966

Group type: EXPERIMENTAL
Intervention: T14 (triple therapy for 14 days; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, all given twice daily)
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: C10 (concomitant therapy for 10 days; lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg, all given twice daily)
Number of subjects: 1620

Group type: EXPERIMENTAL
Intervention: BQ10 (bismuth quadruple therapy for 10 days; bismuth tripotassium dicitrate 300 mg four times a day, lansoprazole 30 mg twice daily, tetracycline 500 mg four times a day, and metronidazole 500 mg three times a day)
Number of subjects: 1620
Study: 28079023

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 647

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 647
Study: 25476726

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: McCoy laryngoscope
Number of subjects: 6
Study: 23717424

Group type: EXPERIMENTAL
Intervention: Tailored education package consisting of multimedia falls prevention information with trained health professional follow-up
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 21107998

Group type: EXPERIMENTAL
Intervention: Smoking tobacco and/or cannabis
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Using both substances (tobacco and cannabis)
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Cannabis and tobacco use
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Disordered eating, depressive symptoms, and cannabis use
Number of subjects: 744
Study: 19694599

Group type: EXPERIMENTAL
Intervention: Telehealth (TH), n = 70
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard Care (SC), n = 68
Number of subjects: 138
Study: 17957097

Group type: EXPERIMENTAL
Intervention: High-flux dialyzer (polyamide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low-flux dialyzer (cuprophan)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Switching from low-flux to high-flux dialyzers
Number of subjects: 20
Study: 15014297

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg every 6 h until 36 h after defervescence)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paracetamol (12 mg/kg every 6 h until 36 h after defervescence)
Number of subjects: 80
Study: 11716884

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy (20 Gy in ten daily fractions over 2 weeks with 500 mg/m(2) fluorouracil intravenously on days 1‐3, repeated after 2 weeks)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (intravenous fluorouracil 425 mg/m(2) and folinic acid 20 mg/m(2) daily for 5 days, monthly for 6 months)
Number of subjects: 541
Study: 9150709

Group type: EXPERIMENTAL
Intervention: Males aged 14-23 years
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Females aged 14-23 years
Number of subjects: 634
Study: 8175136

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (14 mg/kg/body wt/day)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 3330593

Group type: EXPERIMENTAL
Intervention: Enoxacin (single 400 mg dose)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Trimethoprim (single 600 mg dose)
Number of subjects: 55
Study: 31764775

Group type: EXPERIMENTAL
Intervention: Individualized intervention (antenatal breastfeeding education and postnatal lactation support)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 352
Study: 29508247

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 15 mg twice daily plus capecitabine 2000 mg/m2/day (Days 1-14)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo plus capecitabine
Number of subjects: 407
Study: 27253708

Group type: EXPERIMENTAL
Intervention: Unilateral SLR
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham SLR
Number of subjects: 10
Study: 25437218

Group type: EXPERIMENTAL
Intervention: Transfusion of the freshest available red blood cells (RBCs) until hospital discharge
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Standard-care red blood cells
Number of subjects: 5000
Study: 22994054

Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule plus tamoxifen citrate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tamoxifen citrate alone
Number of subjects: 120
Study: 20194828

Group type: EXPERIMENTAL
Intervention: Sertraline treatment for 12 weeks, titrated by clinical response
Number of subjects: 217

Group type: COMPARATOR
Intervention: Baseline neuropsychological factors
Number of subjects: 217
Study: 17592912

Group type: EXPERIMENTAL
Intervention: Creatine (3-5 grams per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15787865

Group type: COMPARATOR
Intervention: Oral cetirizine 0.25 mg/kg twice daily for 18 months
Number of subjects: 343
Study: 12455075

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty for noncalcified lesions
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty for calcified lesions
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cutting Balloon (CB) angioplasty with dissections in calcified lesions
Number of subjects: 180

Group type: COMPARATOR
Intervention: Balloon Angioplasty (BA)
Number of subjects: 180
Study: 10516774

Group type: EXPERIMENTAL
Intervention: 4.5 MIU recombinant interferon alfa-2a
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: 9.0 MIU recombinant interferon alfa-2a
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 97
Study: 7669239

Group type: EXPERIMENTAL
Intervention: IDDM mothers breastfeeding
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-IDDM mothers breastfeeding
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: IDDM mothers delivered by Caesarean section
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: IDDM mothers delivered earlier
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: IDDM babies admitted to special care nursery
Number of subjects: 19
Study: 2258894

Group type: EXPERIMENTAL
Intervention: co-dergocrine mesilate/nifedipine (4 mg/40 mg once daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: mefruside/nifedipine (25 mg/40 mg once daily)
Number of subjects: 40
Study: 7422046

Group type: EXPERIMENTAL
Intervention: Local throat analgesia
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 316

Group type: COMPARATOR
Intervention: No specific preparation
Number of subjects: 316
Study: 30261805

Group type: EXPERIMENTAL
Intervention: Telementoring sessions through the TelePain programme
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no telementoring)
Number of subjects: 41
Study: 31303184

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) with 6 mg Fe plus fourteen micronutrients
Number of subjects: 1704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1704
Study: 28215131

Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANGII)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300